Nanjing Leads Biolabs Co.,ltd

This early-stage trial tested the safety and initial effectiveness of a three-drug combination for people with advanced melanoma that cannot be removed by surgery. The study involved 79 participants and aimed to find the safest dose and see if the drugs could help control the can…

This study tested a new combination of two drugs, LBL-007 and tislelizumab, for treating various types of cancer. It involved 98 adults with advanced solid tumors to see if the combination was safe and if it could help shrink their tumors. The main goals were to find the safest d…

This early-stage study tested a new drug called LBL-019, given alone or with an existing immunotherapy, in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatment showed any early signs of h…